RE:RE:RE:ONCY pelareorep + CAR-T therapy as explained by Mayo ClinicRepost: SAN DIEGO, Calif. and CALGARY, AB, April 14, 2022 /CNW/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced the publication of preclinical data demonstrating the synergistic anti-cancer activity of pelareorep combined with chimeric antigen receptor (CAR) T cell therapy in solid tumors. The paper, entitled "Oncolytic virus-mediated expansion of dual-specific CAR T cells improves efficacy against solid tumors in mice," was published in Science Translational Medicine in collaboration with researchers at several prestigious institutions, including the Mayo Clinic and Duke University.
---------------------------------------------------------------------
In summary - the efficacy of pelareorep-loaded CAR T cells was augmented when the murine subjects received a subsequent intravenous dose (boost) of pelareorep, and overall demonstrated the ability of pelareorep-loaded CAR T cells to overcome the three most significant barriers to effective CAR T therapy by dramatically increasing CAR T cell persistence, reversing immunosuppressive TMEs, and reducing antigen escape.